Recap: Fusion Pharmaceuticals Q4 Earnings
Portfolio Pulse from Benzinga Insights
Fusion Pharmaceuticals (NASDAQ:FUSN) reported Q4 earnings with a -15.0% miss on estimated earnings, posting an EPS of $-0.39 against an estimate of $-0.34. Revenue decreased by $140 thousand from the same period last year. The company's past earnings performance shows variability in beating EPS estimates but was followed by a 2.0% drop in share price after last quarter's earnings beat.
March 20, 2024 | 9:30 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Fusion Pharmaceuticals reported a -15.0% miss on estimated earnings for Q4, with an EPS of $-0.39 versus an estimate of $-0.34, and a revenue decrease from the previous year.
The miss on estimated earnings and the year-over-year decrease in revenue are likely to negatively impact investor sentiment in the short term. Historical data shows a 2.0% drop in share price following last quarter's earnings beat, suggesting sensitivity to earnings reports.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100